JP2024542984A5 - - Google Patents
Info
- Publication number
- JP2024542984A5 JP2024542984A5 JP2024525065A JP2024525065A JP2024542984A5 JP 2024542984 A5 JP2024542984 A5 JP 2024542984A5 JP 2024525065 A JP2024525065 A JP 2024525065A JP 2024525065 A JP2024525065 A JP 2024525065A JP 2024542984 A5 JP2024542984 A5 JP 2024542984A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- formula
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263081P | 2021-10-26 | 2021-10-26 | |
| US63/263,081 | 2021-10-26 | ||
| US202263391671P | 2022-07-22 | 2022-07-22 | |
| US63/391,671 | 2022-07-22 | ||
| PCT/US2022/047767 WO2023076303A1 (en) | 2021-10-26 | 2022-10-25 | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542984A JP2024542984A (ja) | 2024-11-19 |
| JP2024542984A5 true JP2024542984A5 (enExample) | 2025-09-09 |
Family
ID=84361163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525065A Pending JP2024542984A (ja) | 2021-10-26 | 2022-10-25 | がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12377106B2 (enExample) |
| EP (1) | EP4422630A1 (enExample) |
| JP (1) | JP2024542984A (enExample) |
| KR (1) | KR20240090898A (enExample) |
| AU (1) | AU2022379494A1 (enExample) |
| CA (1) | CA3236073A1 (enExample) |
| IL (1) | IL312357A (enExample) |
| MX (1) | MX2024004899A (enExample) |
| WO (1) | WO2023076303A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054355A1 (en) | 2003-03-05 | 2007-03-08 | Yuval Reiss | Cbl-b polypeptides, complexes and related methods |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2008033403A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| PL2242749T3 (pl) | 2008-02-05 | 2013-09-30 | Hoffmann La Roche | Nowe pirydynony i pirydazynony |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| EP2566869B1 (en) | 2010-05-07 | 2016-03-02 | Gilead Connecticut, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| MX2014005282A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de 8-fluoroftalazin-1 (2h) -ona. |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014040965A1 (en) | 2012-09-13 | 2014-03-20 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| US9382246B2 (en) | 2013-12-05 | 2016-07-05 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MX2017015574A (es) | 2015-06-02 | 2018-08-09 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
| AU2016297362B2 (en) | 2015-07-17 | 2020-04-16 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as HDAC inhibitors |
| HUE066460T2 (hu) | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| CA3042297A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| WO2018106870A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| EP3746426A4 (en) | 2018-01-29 | 2021-12-29 | Dana Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| CN112584852A (zh) * | 2018-06-19 | 2021-03-30 | 百欧恩泰美国公司 | 新抗原及其用途 |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| AU2020320195A1 (en) | 2019-07-30 | 2022-03-10 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition |
| EP4034140A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| WO2021113557A1 (en) * | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| AU2022310182A1 (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with diminished imid activity |
| CN118019539A (zh) | 2021-07-23 | 2024-05-10 | 纽力克斯治疗公司 | 用于降解BTK并具有增强的IMiD活性的双官能化合物 |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
-
2022
- 2022-10-25 CA CA3236073A patent/CA3236073A1/en active Pending
- 2022-10-25 WO PCT/US2022/047767 patent/WO2023076303A1/en not_active Ceased
- 2022-10-25 IL IL312357A patent/IL312357A/en unknown
- 2022-10-25 JP JP2024525065A patent/JP2024542984A/ja active Pending
- 2022-10-25 US US18/049,547 patent/US12377106B2/en active Active
- 2022-10-25 EP EP22809599.8A patent/EP4422630A1/en active Pending
- 2022-10-25 MX MX2024004899A patent/MX2024004899A/es unknown
- 2022-10-25 AU AU2022379494A patent/AU2022379494A1/en active Pending
- 2022-10-25 KR KR1020247017265A patent/KR20240090898A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024542984A5 (enExample) | ||
| RU2337692C2 (ru) | Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 | |
| EP2167066B1 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders | |
| JP2024507938A5 (enExample) | ||
| JP2019508439A (ja) | 造血器悪性腫瘍の治療のための、ｌｓｄ１阻害剤の組合せ | |
| JP2005506352A5 (enExample) | ||
| ITRM920155A1 (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| RU2008122358A (ru) | Лекарственные формы, содержащие ag013736 | |
| JP2022527398A5 (enExample) | ||
| RU2011102797A (ru) | Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина | |
| RU2600793C2 (ru) | Новый режим приема n-гидрокси-4-{2-[3-(n, n-диметиламинометил)бензофуран-2-илкарбониламино]этокси}бензамида | |
| HU226555B1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| CA3090129A1 (en) | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent | |
| CA2648518A1 (en) | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor | |
| JP2021530543A5 (enExample) | ||
| JP2021522246A5 (enExample) | ||
| JP2019524888A5 (enExample) | ||
| JP2025508016A5 (enExample) | ||
| EA200600377A1 (ru) | Новая композиция | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| EP1578426A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| JP2021530568A5 (enExample) | ||
| US20250041291A1 (en) | Compositions and methods for treating cancer | |
| CN111989092A (zh) | Bet抑制剂和蛋白酶体抑制剂的联合治疗 |